Increasing proportion of clinical trials using noninferiority end points

Clinical Cardiology

Volumn 35, Issue 9, 2012, Pages 522-523

  Murthy, Venkatesh L ^a,b,c   Desai, Nihar R ^a,b,d   Vora, Amit ^b   Bhatt, Deepak L ^a,b,d,e  

^a Division of Cardiovascular Medicine   (United States)

^b Department of Internal Medicine ^*  (United States)

^c Cardiovascular Imaging Program   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e VA BOSTON HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TENECTEPLASE;

ADVERSE OUTCOME; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; CONTINUOUS INFUSION; COST; DOSE RESPONSE; DRUG EFFICACY; EVIDENCE BASED MEDICINE; HEART INFARCTION; HUMAN; HYPOTHESIS; MORTALITY; NONINFERIORITY END POINT; NOTE; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICAL PARAMETERS; STUDY DESIGN; TREATMENT OUTCOME;

CLINICAL TRIALS AS TOPIC; DATA INTERPRETATION, STATISTICAL; HUMANS; RESEARCH DESIGN;

EID: 84866234985     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22040     Document Type: Note

References (8)

1. Lesaffre E, Bluhmki E, Wang-Clow F, et al. The general concepts of an equivalence trial, applied to ASSENT-2, a large-scale mortality study comparing two fibrinolytic agents in acute myocardial infarction. Eur Heart J. 2001; 22: 898-902.
2. Van De Werf F, Adgey J, Ardissino D, et al. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet. 1999; 354: 716-722.
3. International Conference on Harmonisation-Efficacy. Guidance for industry: E9 statistical principles for clinical trials. US Department of Health and Human Services, US Food and Drug Administration; 1998. http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM073137.pdf. Accessed October 3, 2011.
4. Le Henanff A, Giraudeau B, Baron G, et al. Quality of reporting of noninferiority and equivalence randomized trials. JAMA. 2006; 295: 1147-1151.
5. Piaggio G, Elbourne DR, Altman DG, et al. the CONSORT Group. Reporting of noninferiority and equivalence randomized trials. JAMA. 2006; 295: 1152-1160.
6. Previous ACC annual scientific sessions and i2 summits- program planner. CardioSource. http://www.cardiosource.org/Meetings/Previous-Meetings-OLD.aspx. Accessed October 23, 2011.
7. Fleming TR., Current issues in non-inferiority trials. Stat Med. 2008; 27: 317-332.
8. US Government Accountability Office. New drug approval: FDA's consideration of evidence from certain clinical trials (GAO-10-798); 2010. http://www.gao.gov/products/GAO-10-798. Accessed October 3, 2011.